WO2010018563A3 - Compositions et procédés de pronostic d'un lymphome - Google Patents
Compositions et procédés de pronostic d'un lymphome Download PDFInfo
- Publication number
- WO2010018563A3 WO2010018563A3 PCT/IL2009/000764 IL2009000764W WO2010018563A3 WO 2010018563 A3 WO2010018563 A3 WO 2010018563A3 IL 2009000764 W IL2009000764 W IL 2009000764W WO 2010018563 A3 WO2010018563 A3 WO 2010018563A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prognosis
- compositions
- lymphoma
- methods
- derived
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention porte sur des compositions et des procédés de pronostic d'un lymphome malin. Les compositions sont des molécules de micro-ARN associées au pronostic d'un lymphome, ainsi que diverses molécules d'acide nucléique liées à celles-ci ou dérivées de celles-ci.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8801508P | 2008-08-12 | 2008-08-12 | |
US61/088,015 | 2008-08-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010018563A2 WO2010018563A2 (fr) | 2010-02-18 |
WO2010018563A3 true WO2010018563A3 (fr) | 2010-04-15 |
Family
ID=41259376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2009/000764 WO2010018563A2 (fr) | 2008-08-12 | 2009-08-05 | Compositions et procédés de pronostic d'un lymphome |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010018563A2 (fr) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014093924A1 (fr) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Molécules d'acide nucléique modifiées et leurs utilisations |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
WO2014113089A2 (fr) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Polynucléotides capteurs de signal servant à modifier les phénotypes cellulaires |
EP3461904A1 (fr) | 2014-11-10 | 2019-04-03 | ModernaTX, Inc. | Molécules d'acide nucléique de remplacement contenant une quantité réduite d'uracile et leurs utilisations |
WO2017127750A1 (fr) | 2016-01-22 | 2017-07-27 | Modernatx, Inc. | Acides ribonucléiques messagers pour la production de polypeptides de liaison intracellulaires et leurs procédés d'utilisation |
EP3443001A4 (fr) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | Systèmes de biocircuits régulés |
LT3458083T (lt) | 2016-05-18 | 2023-02-10 | Modernatx, Inc. | Polinukleotidai, koduojantys interleukiną-12 (il12), ir jų naudojimas |
WO2017218704A1 (fr) | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Formulations stabilisées de nanoparticules lipidiques |
EP3478313B1 (fr) | 2016-06-29 | 2022-05-04 | CRISPR Therapeutics AG | Matériaux et méthodes pour traiter la sclérose latérale amyotrophique (als) et d'autres troubles associés |
US11427838B2 (en) | 2016-06-29 | 2022-08-30 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders |
EP3478828B1 (fr) | 2016-06-29 | 2024-09-04 | CRISPR Therapeutics AG | Matériels et méthodes de traitement de l'ataxie de friedreich et d'autres troubles associés |
JP7548696B2 (ja) | 2016-07-06 | 2024-09-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛関連障害を処置するための物質及び方法 |
CA3029132A1 (fr) | 2016-07-06 | 2018-01-11 | Crispr Therapeutics Ag | Materiaux et procedes de traitement de troubles lies a la douleur |
AU2017347837A1 (en) | 2016-10-26 | 2019-06-06 | Modernatx, Inc. | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
WO2018089540A1 (fr) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Formulations stabilisées de nanoparticules lipidiques |
AU2018214556A1 (en) | 2017-02-01 | 2019-08-15 | Modernatx, Inc. | Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides |
JP2020508056A (ja) | 2017-02-22 | 2020-03-19 | クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG | 遺伝子編集のための組成物および方法 |
US11407997B2 (en) | 2017-02-22 | 2022-08-09 | Crispr Therapeutics Ag | Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders |
WO2018154462A2 (fr) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Matériaux et procédés pour le traitement de l'ataxie spinocérébelleuse de type 2 (sca2) et d'autres affections ou troubles liés au gène de l'ataxie spinocérébelleuse de type 2 (atxn2) |
EP3585898A1 (fr) | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Matériaux et procédés pour le traitement de l'ataxie spinocérébelleuse de type 1 (sca1) et d'autres états ou troubles liés au gène de l'ataxie spinocérébelleuse de type 1 (atxn1) |
WO2018154418A1 (fr) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Matériaux et procédés pour le traitement de la maladie de parkinson à début précoce (park1) et d'autres états pathologiques ou troubles associés au gène alpha (snca) |
US20200131498A1 (en) | 2017-06-14 | 2020-04-30 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
WO2019046809A1 (fr) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Procédés de fabrication de nanoparticules lipidiques |
WO2019102381A1 (fr) | 2017-11-21 | 2019-05-31 | Casebia Therapeutics Llp | Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante |
WO2019123429A1 (fr) | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Matériaux et méthodes de traitement du syndrome d'usher de type 2a |
WO2019123430A1 (fr) | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Substances et méthodes pour le traitement du syndrome d'usher de type 2a et/ou de la rétinite pigmentaire autosomique récessive (arrp) non syndromique |
JP2021512090A (ja) | 2018-01-30 | 2021-05-13 | モデルナティーエックス, インコーポレイテッド | 免疫細胞に薬剤を送達するための組成物及び方法 |
WO2019200171A1 (fr) | 2018-04-11 | 2019-10-17 | Modernatx, Inc. | Arn messager comprenant des éléments d'arn fonctionnels |
EP3806888B1 (fr) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Constructions régulatrices dérivées de pde5 et procédés d'utilisation en immunothérapie |
US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
EP3870600A1 (fr) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Régulation de protéine accordable par er |
CA3128215A1 (fr) | 2019-01-31 | 2020-08-06 | Modernatx, Inc. | Procedes de preparation de nanoparticules lipidiques |
AU2020235865A1 (en) | 2019-03-08 | 2021-09-23 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
WO2020263985A1 (fr) | 2019-06-24 | 2020-12-30 | Modernatx, Inc. | Arn messager comprenant des éléments d'arn fonctionnels et leurs utilisations |
WO2020263883A1 (fr) | 2019-06-24 | 2020-12-30 | Modernatx, Inc. | Arn messager résistant à l'endonucléase et utilisations correspondantes |
WO2021046451A1 (fr) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions et méthodes de régulation de protéine accordable dhfr |
IL294866A (en) | 2020-01-31 | 2022-09-01 | Modernatx Inc | Methods for preparing fat nanoparticles |
EP4185274A1 (fr) | 2020-07-24 | 2023-05-31 | Strand Therapeutics Inc. | Nanoparticule de nanoparticule lipidique comprenant des nucléotides modifiés |
EP4192432A1 (fr) | 2020-08-06 | 2023-06-14 | ModernaTX, Inc. | Procédés de préparation de nanoparticules lipidiques |
MX2023008002A (es) | 2021-01-08 | 2023-08-25 | Constructos de expresion y usos de estos. | |
WO2022233880A1 (fr) | 2021-05-03 | 2022-11-10 | Curevac Ag | Séquence d'acide nucléique améliorée pour l'expression spécifique de type cellulaire |
WO2023166425A1 (fr) | 2022-03-01 | 2023-09-07 | Crispr Therapeutics Ag | Procédés et compositions pour le traitement d'affections liées à la protéine 3 de type angiopoïétine (angptl3) |
WO2023212618A1 (fr) | 2022-04-26 | 2023-11-02 | Strand Therapeutics Inc. | Nanoparticules lipidiques comprenant un réplicon d'encéphalite équine du vénézuela (vee) et leurs utilisations |
WO2024026487A1 (fr) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Compositions de nanoparticules lipidiques comprenant des dérivés phospholipidiques et utilisations associées |
WO2024026475A1 (fr) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Compositions pour administration à des cellules souches et progénitrices hématopoïétiques (hspc) et utilisations associées |
WO2024026482A1 (fr) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Compositions de nanoparticules lipidiques comprenant des dérivés lipidiques de surface et utilisations associées |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060105360A1 (en) * | 2004-02-09 | 2006-05-18 | Croce Carlo M | Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features |
EP1676914A1 (fr) * | 2003-09-22 | 2006-07-05 | Aichi Prefecture | Type de lymphome pathologique et procede d'evaluation de diagnostic |
US20070072204A1 (en) * | 2005-05-02 | 2007-03-29 | Hannon Gregory J | Compositions and methods for cancer diagnosis and treatment |
WO2007148235A2 (fr) * | 2006-05-04 | 2007-12-27 | Rosetta Genomics Ltd | Acides nucléiques apparentés au cancer |
-
2009
- 2009-08-05 WO PCT/IL2009/000764 patent/WO2010018563A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1676914A1 (fr) * | 2003-09-22 | 2006-07-05 | Aichi Prefecture | Type de lymphome pathologique et procede d'evaluation de diagnostic |
US20060105360A1 (en) * | 2004-02-09 | 2006-05-18 | Croce Carlo M | Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features |
US20070072204A1 (en) * | 2005-05-02 | 2007-03-29 | Hannon Gregory J | Compositions and methods for cancer diagnosis and treatment |
WO2007148235A2 (fr) * | 2006-05-04 | 2007-12-27 | Rosetta Genomics Ltd | Acides nucléiques apparentés au cancer |
Non-Patent Citations (14)
Title |
---|
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 841A, ISSN: 0006-4971 * |
BLOOD, vol. 110, no. 11, Part 1, November 2007 (2007-11-01), 49TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 08 -11, 2007, pages 1049A, ISSN: 0006-4971 * |
CALIN G A ET AL: "A MICRORNA SIGNATURE ASSOCIATED WITH PROGNOSIS AND PROGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 353, no. 17, 27 October 2005 (2005-10-27), pages 1793 - 1801, XP009058593, ISSN: 1533-4406 * |
CALIN GEORGE A ET AL: "MicroRNA signatures in human cancers", NATURE REVIEWS. CANCER, NATUR PUBLISHING GROUP, LONDON, GB, vol. 6, no. 11, 1 November 2006 (2006-11-01), pages 857 - 866, XP002473506, ISSN: 1474-175X * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), LAWRIE CHARLES H ET AL: "MicroRNA expression profiling of diffuse large B-cell lymphoma reveals differences between germinal center-like and activated B cell-like subtypes.", XP002554909, Database accession no. PREV200600185370 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2007 (2007-11-01), ROBERTUS JAN-LUKAS ET AL: "Differences in the C13orf25 miRNA cluster in non-Hodgkin lymphoma and normal B-Cell subtypes", XP002554910, Database accession no. PREV200800218858 * |
EIS P S ET AL: "Accumulation of miR-155 and BIC RNA in human B cell lymphomas", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 102, no. 10, 1 March 2005 (2005-03-01), pages 3627 - 3632, XP002396794, ISSN: 0027-8424 * |
HE LIN ET AL: "A microRNA polycistron as a potential human oncogene", NATURE (LONDON), vol. 435, no. 7043, June 2005 (2005-06-01), pages 828 - 833, XP002554907, ISSN: 0028-0836 * |
LAWRIE CHARLES H ET AL: "Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma", BRITISH JOURNAL OF HAEMATOLOGY,, vol. 141, no. 5, 3 March 2008 (2008-03-03), pages 672 - 675, XP002545705 * |
LAWRIE CHARLES H ET AL: "MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma", INTERNATIONAL JOURNAL OF CANCER, vol. 121, no. 5, September 2007 (2007-09-01), pages 1156 - 1161, XP002554905, ISSN: 0020-7136 * |
OTA A ET AL: "Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 64, no. 9, 1 May 2004 (2004-05-01), pages 3087 - 3095, XP002996247, ISSN: 0008-5472 * |
ROEHLE ANJA ET AL: "MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas.", BRITISH JOURNAL OF HAEMATOLOGY SEP 2008, vol. 142, no. 5, 5 June 2008 (2008-06-05), pages 732 - 744, XP002554906, ISSN: 1365-2141 * |
TAGAWA HIROYUKI ET AL: "Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development", CANCER SCIENCE, vol. 98, no. 9, September 2007 (2007-09-01), pages 1482 - 1490, XP002554908, ISSN: 1347-9032 * |
TANZER A ET AL: "Molecular Evolution of a MicroRNA Cluster", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 339, no. 2, 28 May 2004 (2004-05-28), pages 327 - 335, XP004506520, ISSN: 0022-2836 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010018563A2 (fr) | 2010-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010018563A3 (fr) | Compositions et procédés de pronostic d'un lymphome | |
AU2016204376A1 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer | |
WO2009108866A3 (fr) | Signatures en micro-arn associées à la cytogénétique et au pronostic dans la leucémie myéloïde aiguë (aml) et leurs utilisations | |
WO2009111643A3 (fr) | Marqueurs microrna pour la récurrence d’un cancer colorectal | |
WO2010099161A8 (fr) | Microarn chez les non-fumeurs et méthodes et matières apparentées | |
WO2009108860A3 (fr) | Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate | |
WO2009061381A3 (fr) | Variants d'alpha-amylase à propriétés modifiées | |
WO2009153775A3 (fr) | Procédés permettant de différencier différents types de cancers du poumon | |
WO2009108217A3 (fr) | Compositions comprenant un arnsi de k-ras et procédés d’utilisation | |
WO2007139723A8 (fr) | Amorces d'oligonucléotides chimiquement modifiées pour l'amplification de l'acide nucléique | |
WO2007148235A3 (fr) | Acides nucléiques apparentés au cancer | |
WO2010127304A3 (fr) | Procédés de séquençage | |
WO2010048585A3 (fr) | Composés oligomères et méthodes | |
WO2008069906A3 (fr) | Expression numérisée de l'analyse génétique | |
WO2009012263A3 (fr) | Micro-arn à spécificité cellulaire et compositions et utilisations de ces micro-arn | |
WO2008067423A3 (fr) | Procédé d'amélioration de l'introduction d'adn dans des cellules bactériennes | |
WO2011156654A3 (fr) | Caractérisation de voies de cellules | |
WO2009039189A3 (fr) | Compositions comprenant des arnsi de stat3 et leurs procédés d'utilisation | |
WO2010045384A3 (fr) | Arn courts en épingles à cheveux destinés à inhiber l’expression des gènes | |
WO2007014077A3 (fr) | Modulation de l'arni du gene rho-a et utilisations de celle-ci | |
WO2009153774A3 (fr) | Compositions et procédés pour le pronostic du cancer des ovaires | |
WO2011160052A3 (fr) | Procédés et compositions associés à des arn-endonucléases spécifiques d'une séquence | |
WO2009135218A3 (fr) | Détection de prédisposition génétique à des pathologies associées à l'arthrose | |
WO2009120712A3 (fr) | Compositions et procédés pour diagnostiquer et traiter un mélanome | |
WO2009135219A3 (fr) | Détection d'une prédisposition génétique à des états associés à l'ostéoarthrite |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09787509 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09787509 Country of ref document: EP Kind code of ref document: A2 |